19-17831723-G-A

Variant summary

Our verdict is Likely benign. The variant received -3 ACMG points: 0P and 3B. BP4_ModerateBP6

The NM_000215.4(JAK3):​c.2756C>T​(p.Ala919Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000143 in 1,611,676 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A919P) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.000059 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000096 ( 0 hom. )

Consequence

JAK3
NM_000215.4 missense

Scores

2
16

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:1

Conservation

PhyloP100: 1.09

Publications

3 publications found
Variant links:
Genes affected
JAK3 (HGNC:6193): (Janus kinase 3) The protein encoded by this gene is a member of the Janus kinase (JAK) family of tyrosine kinases involved in cytokine receptor-mediated intracellular signal transduction. It is predominantly expressed in immune cells and transduces a signal in response to its activation via tyrosine phosphorylation by interleukin receptors. Mutations in this gene are associated with autosomal SCID (severe combined immunodeficiency disease). [provided by RefSeq, Jul 2008]
JAK3 Gene-Disease associations (from GenCC):
  • T-B+ severe combined immunodeficiency due to JAK3 deficiency
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Labcorp Genetics (formerly Invitae), Laboratory for Molecular Medicine, ClinGen, Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -3 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.10622984).
BP6
Variant 19-17831723-G-A is Benign according to our data. Variant chr19-17831723-G-A is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 565744.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
JAK3NM_000215.4 linkc.2756C>T p.Ala919Val missense_variant Exon 20 of 24 ENST00000458235.7 NP_000206.2
JAK3NM_001440439.1 linkc.2756C>T p.Ala919Val missense_variant Exon 20 of 24 NP_001427368.1
JAK3XR_007066796.1 linkn.2891C>T splice_region_variant, non_coding_transcript_exon_variant Exon 20 of 20

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
JAK3ENST00000458235.7 linkc.2756C>T p.Ala919Val missense_variant Exon 20 of 24 5 NM_000215.4 ENSP00000391676.1

Frequencies

GnomAD3 genomes
AF:
0.0000591
AC:
9
AN:
152174
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000193
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000249
AC:
6
AN:
240618
AF XY:
0.0000303
show subpopulations
Gnomad AFR exome
AF:
0.000344
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000959
AC:
14
AN:
1459502
Hom.:
0
Cov.:
33
AF XY:
0.0000110
AC XY:
8
AN XY:
726056
show subpopulations
African (AFR)
AF:
0.000239
AC:
8
AN:
33460
American (AMR)
AF:
0.00
AC:
0
AN:
44536
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26062
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39672
South Asian (SAS)
AF:
0.0000232
AC:
2
AN:
86122
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
52096
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5764
European-Non Finnish (NFE)
AF:
0.00000270
AC:
3
AN:
1111502
Other (OTH)
AF:
0.0000166
AC:
1
AN:
60288
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.436
Heterozygous variant carriers
0
1
2
4
5
6
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000591
AC:
9
AN:
152174
Hom.:
0
Cov.:
32
AF XY:
0.0000673
AC XY:
5
AN XY:
74336
show subpopulations
African (AFR)
AF:
0.000193
AC:
8
AN:
41456
American (AMR)
AF:
0.00
AC:
0
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5174
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4830
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10614
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000147
AC:
1
AN:
68030
Other (OTH)
AF:
0.00
AC:
0
AN:
2090
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1
2
3
4
5
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0000282
Hom.:
0
Bravo
AF:
0.0000869
ExAC
AF:
0.00000827
AC:
1

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

JAK3-related disorder Uncertain:1
Feb 29, 2024
PreventionGenetics, part of Exact Sciences
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

The JAK3 c.2756C>T variant is predicted to result in the amino acid substitution p.Ala919Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.026% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

Inborn genetic diseases Uncertain:1
Oct 07, 2024
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.2756C>T (p.A919V) alteration is located in exon 20 (coding exon 19) of the JAK3 gene. This alteration results from a C to T substitution at nucleotide position 2756, causing the alanine (A) at amino acid position 919 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

T-B+ severe combined immunodeficiency due to JAK3 deficiency Benign:1
Oct 29, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.091
BayesDel_addAF
Benign
-0.21
T
BayesDel_noAF
Benign
-0.23
CADD
Benign
15
DANN
Benign
0.96
DEOGEN2
Benign
0.38
T;T;.
Eigen
Benign
-0.81
Eigen_PC
Benign
-0.87
FATHMM_MKL
Benign
0.14
N
LIST_S2
Benign
0.51
T;.;T
M_CAP
Uncertain
0.16
D
MetaRNN
Benign
0.11
T;T;T
MetaSVM
Benign
-0.85
T
MutationAssessor
Benign
0.53
N;N;N
PhyloP100
1.1
PrimateAI
Uncertain
0.62
T
PROVEAN
Benign
-0.84
N;N;N
REVEL
Benign
0.19
Sift
Benign
0.30
T;T;T
Sift4G
Benign
0.29
T;T;T
Vest4
0.27
ClinPred
0.024
T
GERP RS
1.6
Varity_R
0.12
gMVP
0.78
Mutation Taster
=72/28
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs767424476; hg19: chr19-17942532; API